Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLO: maintenance olaparib in germline BRCA-mutated metastatic pancreatic cancer
NL-OMON55810Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) comparing Olaparib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Apr 2016; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON55810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55810.